Page last updated: 2024-10-27

fluoxetine and Autoimmune Demyelinating Disease, Peripheral

fluoxetine has been researched along with Autoimmune Demyelinating Disease, Peripheral in 1 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Montgomery, SA1
Gabriel, R1
James, D1
Hawley, C1
Burkitt, P1

Other Studies

1 other study available for fluoxetine and Autoimmune Demyelinating Disease, Peripheral

ArticleYear
The specificity of the zimelidine reaction.
    International clinical psychopharmacology, 1989, Volume: 4, Issue:1

    Topics: Chemical and Drug Induced Liver Injury; Depressive Disorder; Drug Hypersensitivity; Fluoxetine; Huma

1989